Shares of Provention Bio, Inc. (NASDAQ:PRVB – Get Rating) have been given a consensus recommendation of “Buy” by the nine brokerages that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $16.25.
PRVB has been the topic of several recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Provention Bio in a research report on Friday, April 1st. Zacks Investment Research raised Provention Bio from a “sell” rating to a “hold” rating in a report on Saturday, May 7th.
Shares of NASDAQ:PRVB opened at $4.17 on Wednesday. The business’s 50-day moving average is $5.11 and its 200 day moving average is $5.75. Provention Bio has a 1 year low of $3.40 and a 1 year high of $9.70. The firm has a market capitalization of $267.05 million, a P/E ratio of -2.53 and a beta of 2.75.
A number of institutional investors have recently bought and sold shares of PRVB. Denali Advisors LLC acquired a new stake in Provention Bio during the fourth quarter worth about $39,000. Royal Bank of Canada grew its holdings in Provention Bio by 44.9% during the second quarter. Royal Bank of Canada now owns 6,534 shares of the company’s stock worth $55,000 after acquiring an additional 2,026 shares during the period. J.W. Cole Advisors Inc. acquired a new stake in Provention Bio during the fourth quarter worth about $73,000. Sawtooth Solutions LLC acquired a new stake in Provention Bio during the first quarter worth about $75,000. Finally, Ensign Peak Advisors Inc purchased a new position in Provention Bio during the fourth quarter worth approximately $82,000. 37.39% of the stock is currently owned by hedge funds and other institutional investors.
About Provention Bio (Get Rating)
Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease.
- Get a free copy of the StockNews.com research report on Provention Bio (PRVB)
- 3 Intriguing Stocks With Sub-10 P/E Ratios
- Snap Inc: Revised Guidance & Steeping Losses
- Time to Buy Take-Two Interactive Stock
- 3 Software Plays Showing Signs of Recovery
- It’s Time To PLAY With Dave & Buster’s
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.